First-in-class siRNA therapeutic targeting protein S to prevent bleeding and joint/bone damage

• Unité de recherche: INNOSUISSE
• Numéro de projet: 134.426 IP-LS
• Titre du projet anglais: First-in-class siRNA therapeutic targeting protein S to prevent bleeding and joint/bone damage

Mots-clé (Anglais)

Life sciences, Biotechnology and processing

Résumé des résultats (Abstract) (Anglais)

BnF-001 is a first-in-class siRNA providing a controlled targeting of protein S as a universal treatment for hemophilia and allied bleeding disorders by preventing bleeding and preserving joint and bone health. Preclinical studies address candidate selection, development, safety and efficacy.